Contents

Search

alvimopan (Entereg, ADL-8-2698)

Indications: 1) prevention of post-operative ileus - decreases postoperative ileus after abdominal surgery in patients with inflammatory bowel disease [3] 2) reduces post-operative nausea & vomiting without increased need for post-operative analgesia Precautions: - hospitals must be specially certified before using the drug Dosage: - 6 mg just before surgery, then 6 mg BID - limited to 15 doses Pharmacokinetics: 1) poorly absorbed from GI tract 2) does not readily cross blood brain barrier Adverse effects: - hypocalcemia - anemia - constipation, dyspepsia, flatulence - increased risk of myocardial infarction? [2] Mechanism of action: 1) investigational opioid receptor antagonist (10/01) 2) reduces post-operative nausea & vomiting

General

opioid receptor antagonist or narcotic antagonist

Properties

INHIBITS: opiate

Database Correlations

PUBCHEM cid=156035

References

  1. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001 Sep 27;345(13):935-40. PMID: 11575284 Free Article
  2. FDA press release http://www.fda.gov/bbs/topics/NEWS/2008/NEW01838.html
  3. Bachert A. Alvimopan Speeds GI Recovery in IBD Patients - Significantly decreased length of stay, researchers reported at AIBD. MedPage Today, Nov 10, 2017 - Jang J, et al The use of alvimopan as prophylaxis against post-operative ileus after bowel resection in patients with inflammatory bowel disease. Advances in Inflammatory Bowel Diseases (AIBD) 2017 Poster 004.